Cargando…

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mistry, Jayna J, Hellmich, Charlotte, Lambert, Amelia, Moore, Jamie A, Jibril, Aisha, Collins, Angela, Bowles, Kristian M, Rushworth, Stuart A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117650/ https://www.ncbi.nlm.nih.gov/pubmed/33985565 http://dx.doi.org/10.1186/s40364-021-00291-y

Ejemplares similares

Daratumumab inhibits acute myeloid leukemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells
por: Mistry, Jayna J., et al.
Publicado: (2020)

LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation
por: Moore, Jamie A., et al.
Publicado: (2022)

ARQ531: the therapy that targets multiple pathways in acute myeloid leukemia
por: Hellmich, Charlotte, et al.
Publicado: (2020)

P469: ACUTE MYELOID LEUKEMIA DRIVES BCL-2 UPREGULATION IN NON MALIGNANT HSPCS WHICH IS TARGETED BY VENETOCLAX AND CAUSES CYTOPENIA
por: Fowler-Shorten, Dominic, et al.
Publicado: (2023)

P1341: LC3-ASSOCIATED PHAGOCYTOSIS IS IMPAIRED IN BONE MARROW MACROPHAGES DURING AGEING LEADING TO DEFECTIVE PHAGOCYTOSIS AND ACCUMULATION OF APOPTOTIC DEBRIS WITHIN THE BONE MARROW.
por: Hampton, Katherine, et al.
Publicado: (2023)

Free fatty-acid transport via CD36 drives β-oxidation-mediated hematopoietic stem cell response to infection
por: Mistry, Jayna J., et al.
Publicado: (2021)

P431: ACTIVATION OF MACROPHAGE STING ENHANCES PHAGOCYTOSIS OF ACUTE MYELOID LEUKAEMIA
por: Maynard, Rebecca, et al.
Publicado: (2023)

p16INK4A-dependent senescence in the bone marrow niche drives age-related metabolic changes of hematopoietic progenitors
por: Hellmich, Charlotte, et al.
Publicado: (2022)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

P423: ACUTE MYELOID LEUKEMIA REPROGRAMS LIPID METABOLISM BY DOWNREGULATING CD36 EXPRESSION IN HEPATOCYTES.
por: Maynard, Rebecca, et al.
Publicado: (2023)

Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche
por: Maynard, Rebecca S., et al.
Publicado: (2022)

Bone Marrow Senescence and the Microenvironment of Hematological Malignancies
por: Hellmich, Charlotte, et al.
Publicado: (2020)

PGC-1α induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma
por: Kumar, Prakrit R., et al.
Publicado: (2022)

The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma
por: Piddock, Rachel E., et al.
Publicado: (2017)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
por: Stanulla, Martin, et al.
Publicado: (2023)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism
por: Rushworth, Stuart A, et al.
Publicado: (2010)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
por: Knight, Tristan, et al.
Publicado: (2019)

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
por: Maiti, Abhishek, et al.
Publicado: (2022)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia
por: Zhou, Cheng, et al.
Publicado: (2022)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
por: Oyogoa, Emmanuella, et al.
Publicado: (2023)

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia
por: Liberatore, Carmine, et al.
Publicado: (2023)

Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
por: Nakamura, Ayano, et al.
Publicado: (2021)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
por: Sciumè, M., et al.
Publicado: (2022)

An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia
por: Przedborski, Michelle, et al.
Publicado: (2022)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
por: Sciumè, Mariarita, et al.
Publicado: (2023)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h0gsb3d7b0c2071kcgmkhq5cbr